摘要
Despite the development of chemoresistance as a major concern in prostate cancer therapy, the underlying mechanisms remain elusive. In this report, we demonstrate that DU145-derived prostate cancer stem cells (PCSCs) progress slowly with more cells accumulating in the Cl phase in comparison to DU145 non-PCSCs. Consistent with the important role of the AKT pathway in promoting G1 progression, DU145 PCSCs were less sensitive to growth factor-induced activation of AKT in comparison to non-PCSCs. In response to etoposide (one of the most commonly used chemotherapeutic drugs), DU145 PCSCs survived significantly better than non-PCSCs. In addition to etoposide, PCSCs demonstrated increased resistance to docetaxel, a taxane drug that is commonly used to treat castration-resistant prostate cancer. Etoposide produced elevated levels of gamma H2AX and triggered a robust G2/M arrest along with a coordinated reduction of the G1 population in PCSCs compared to non-PCSCs, suggesting that elevated gamma H2AX plays a role in the resistance of PCSCs to etoposide-induced cytotoxicity. We have generated xenograft tumors from DU145 PCSCs and non-PCSCs. Consistent with the knowledge that PCSCs produce xenograft tumors with more advanced features, we were able to demonstrate that PCSC-derived xenograft tumors displayed higher levels of gamma H2AX and p-CHK1 compared to non-PCSC-produced xenograft tumors. Collectively, our research suggests that the elevation of DNA damage response contributes to PCSC-associated resistance to genotoxic reagents.
学科与关键词
- DNA damage response and resistance of cancer stem cellsEtna Abad E; Dmitry Graifer; Alex LyakhovichCancer Letters, 2020.
- CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancerChen, Binshen; Zhang, Yiming; Li, Chaoming; Xu, Peng; Gao, Yubo; Xu, Yawen*Archives of Medical Science, 2021, 17(1): 152-165.被引 16
- Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer.Li, Sanqiang; Li, Ruifang; Ma, Yu; Zhang, Cong; Huang, Tao; Zhu, ShaJournal of Cellular and Molecular Medicine, 2019, 23(3): 1987-2000.
